Clinical Trial Update: Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of paclitaxel with bavituximab in HER2-negative metastatic breast cancer has completed; no efficacy results are provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Male Breast Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Arizona | Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer | Phase 1 | Status: COMPLETED